Table 3.
Percentages of CD4+ T-cell subsets in HIV-infected children
| *P-value for difference between | ||||||
|---|---|---|---|---|---|---|
| Phenotype | control | LTA | RP | LTA and control | RP and control | LTA and RP |
| Memory/naive | ||||||
| CD4+ CD45RO+ HLA-DR+ | 3·4 ± 0·4 | 3·2 ± 0·4 | 32·2 ± 5·9 | 0·962 | 0·000 | 0·000 |
| CD4+ CD45RO+ | 50·9 ± 3·9 | 33·7 ± 3·3 | 71·9 ± 6·4 | 0·005 | 0·042 | 0·001 |
| CD4+ CD45RA-CD62L+ | 35·4 ± 1·3 | 28·9 ± 2·2 | 47·8 ± 3·2 | 0·019 | 0·005 | 0·000 |
| CD4+ CD7- | 11·2 ± 1·3 | 6·1 ± 1·0 | 24·3 ± 7·0 | 0·018 | 0·371 | 0·005 |
| CD4+ CD28- | 1·8 ± 0·9 | 0·8 ± 0·3 | 11·9 ± 6·5 | 0·432 | 0·371 | 0·070 |
| CD4+ CD28-CD7- | 1·0 ± 0·6 | 0·6 ± 0·3 | 11·3 ± 6·4 | 0·530 | 0·310 | 0·109 |
| CD4+ CD45RA+ CD62L+ | 46·3 ± 2·9 | 65·1 ± 2·9 | 28·3 ± 6·5 | 0·001 | 0·212 | 0·000 |
| CD4+ CD28+ | 98·3 ± 0·9 | 99·2 ± 0·3 | 88·1 ± 6·5 | 0·432 | 0·371 | 0·070 |
| CD4+ CD45RA+ | 47·0 ± 2·9 | 65·4 ± 2·9 | 29·3 ± 6·5 | 0·001 | 0·192 | 0·000 |
| CD4+ CD62L+ | 81·7 ± 2·1 | 94·0 ± 0·9 | 76·2 ± 4·6 | 0·000 | 0·752 | 0·000 |
| Activated | ||||||
| CD4+ HLA-DR+ CD38+ | 1·5 ± 0·2 | 3·5 ± 1·0 | 28·1 ± 5·4 | 0·005 | 0·000 | 0·000 |
| CD4+ HLA-DR-CD38+ | 60·8 ± 2·6 | 75·7 ± 1·7 | 42·6 ± 5·8 | 0·001 | 0·074 | 0·000 |
| CD4+ HLA-DR+ CD38- | 2·5 ± 0·3 | 1·9 ± 0·2 | 12·1 ± 2·4 | 0·230 | 0·000 | 0·000 |
| CD4+ HLA-DR+ | 3·9 ± 0·4 | 5·4 ± 1·2 | 40·2 ± 6·0 | 0·230 | 0·000 | 0·000 |
| CD4+ CD38+ | 62·3 ± 2·7 | 79·1 ± 1·8 | 70·6 ± 4·9 | 0·001 | 0·084 | 0·585 |
LTA, long-term asymptomatic HIV-infected children. RP, rapid progressors HIV-infected children. Control, age-matched HIV-negative healthy children. RFI, relative fluorescence intensities. Values are expressed as mean ± s.e.m.
*
Difference between LTA, RP and Control (level of significance).